Glykopyrroniumbromidi Accord

Glykopyrroniumbromidi Accord contains the anticholinergic agent glycopyrronium bromide in an injectable form. It is a prescription‑only product marketed in the European Union and is used as a bronchodilator and antisecretory agent. The medication works by competitively blocking muscarinic acetylcholine receptors, which reduces secretions and relaxes airway smooth muscle.

Glykopyrroniumbromidi Accord is indicated for several clinical situations where reduction of secretions or bronchodilation is desired.

- Pre‑operative reduction of salivary and respiratory secretions to improve airway management. - Adjunct therapy in chronic obstructive pulmonary disease (COPD) to aid bronchodilation. - Treatment of hyperhidrosis when other options are insufficient. - Management of excessive bronchial secretions in certain respiratory conditions. - Supportive care in anesthesia to control airway secretions.

Side effects of glycopyrrium bromide may vary in frequency and severity.

Common: - Dry mouth (xerostomia). - Throat irritation. - Nasal dryness. - Blurred vision. - Constipation. - Urinary retention.

Serious: - Severe allergic reaction (anaphylaxis). - Acute angle‑closure glaucoma. - Significant tachycardia. - Cardiac arrhythmias. - Marked hypotension. - Persistent urinary retention requiring catheterisation.

Before using Glykopyrroniumbromidi Accord, clinicians should consider several safety factors.

- Assess for a history of glaucoma, especially narrow‑angle type. - Evaluate cardiac function in patients with known arrhythmias or tachycardia. - Use caution in individuals with urinary retention or prostate enlargement. - Monitor for signs of hypersensitivity during and after administration. - Adjust dose or avoid use in patients with severe gastrointestinal motility disorders. - Consider renal or hepatic impairment when determining dosing frequency.

Glycopyrronium bromide may interact with other medications, requiring careful management.

Avoid: - Other anticholinergic agents (e.g., atropine, scopolamine) that may increase anticholinergic burden. - Drugs that prolong the QT interval, as additive cardiac effects are possible.

Use with caution: - Beta‑agonists or other bronchodilators, monitoring for excessive cardiovascular stimulation. - Medications that lower intra‑ocular pressure, due to potential glaucoma risk. - Opioids, as anticholinergic effects may mask constipation. - Diuretics, because of possible additive effects on electrolyte balance.